

# Leonhard MÃ¼llauer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4023224/publications.pdf>

Version: 2024-02-01

161  
papers

5,924  
citations

71102

41  
h-index

85541

71  
g-index

163  
all docs

163  
docs citations

163  
times ranked

7885  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. <i>Oral Oncology</i> , 2022, 124, 105634.	1.5	9
3	Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. <i>Cancer Research</i> , 2022, 82, P1-02-06-P1-02-06.	0.9	0
4	Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report. <i>Frontiers in Neuroscience</i> , 2022, 16, 810645.	2.8	3
5	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. , 2022, 10, e003420.		11
6	Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2022, 29, 2453-2462.	3.3	7
7	Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors. <i>Cancers</i> , 2022, 14, 1936.	3.7	1
8	DIPG-60. Avapritinib for targeting PDGFRA in H3K27M “ mutated diffuse midline glioma. <i>Neuro-Oncology</i> , 2022, 24, i32-i32.	1.2	3
9	PATH-09. Liquid biopsy of cerebrospinal fluid enables detecting and monitoring of MYC/MYCN amplification in pediatric CNS malignancies. <i>Neuro-Oncology</i> , 2022, 24, i160-i160.	1.2	0
10	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. <i>British Journal of Cancer</i> , 2022, 127, 1162-1171.	6.4	3
11	Molecularly guided treatment of metastatic parotid gland carcinoma in adults. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 32-40.	1.9	4
12	Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 48.	2.5	13
13	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
14	LAG-3 expression in the inflammatory microenvironment of glioma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 533-539.	2.9	22
15	Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 292.	2.5	15
16	Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 593.	2.5	11
17	Molecular Pathology of Cancer: The Past, the Present, and the Future. <i>Journal of Personalized Medicine</i> , 2021, 11, 676.	2.5	4
18	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia “ microenvironment-dependent lineage differentiation derived from a common progenitor?. <i>Journal of Hematopathology</i> , 2021, 14, 325-332.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	3.7	9
20	INN-17. RESPONSE TO AVAPRITINIB IN A PEDIATRIC SPINAL CORD H3K27M-MUTANT GLIOMA PATIENT. <i>Neuro-Oncology</i> , 2021, 23, vi108-vi108.	1.2	2
21	Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. <i>Biomolecules</i> , 2021, 11, 1700.	4.0	5
22	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	3.5	21
23	Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e49-e53.	2.6	3
24	Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers. <i>Cancers</i> , 2020, 12, 3381.	3.7	2
25	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	4.5	17
26	Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093861.	3.2	5
27	Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI. <i>Journal of Personalized Medicine</i> , 2020, 10, 188.	2.5	7
28	Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092863.	3.2	12
29	Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2020, 10, 272.	2.5	5
30	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. <i>Journal of Personalized Medicine</i> , 2020, 10, 290.	2.5	18
31	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. <i>Clinical Cancer Research</i> , 2020, 26, 3819-3830.	7.0	23
32	Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. <i>Oncologist</i> , 2020, 25, e1060-e1069.	3.7	4
33	Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 1979-1988.	1.9	3
34	Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 548.	3.7	13
35	Heat shock protein 90 $\alpha$ in thymic epithelial tumors and non-thymomatous myasthenia gravis. <i>Oncolimmunology</i> , 2020, 9, 1756130.	4.6	6
36	STAT5 is Expressed in CD34+/CD38 $\alpha$ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	3.7	12

#	ARTICLE	IF	CITATIONS
37	Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. <i>Frontiers in Oncology</i> , 2020, 10, 593852.	2.8	14
38	The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 11-26.	0.5	5
39	Genomic alterations in thymoma—molecular pathogenesis?. <i>Journal of Thoracic Disease</i> , 2020, 12, 7536-7544.	1.4	9
40	HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii351-iii352.	1.2	0
41	Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy. <i>Case Reports in Obstetrics and Gynecology</i> , 2019, 2019, 1-8.	0.3	3
42	VARIFL—Web-Based Automatic Variant Identification, Filtering and Annotation of Amplicon Sequencing Data. <i>Journal of Personalized Medicine</i> , 2019, 9, 10.	2.5	1
43	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
44	PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1334.	2.8	14
45	Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. <i>Scientific Reports</i> , 2019, 9, 17359.	3.3	12
46	Clinical prognostic scores for patients with thymic epithelial tumors. <i>Scientific Reports</i> , 2019, 9, 18581.	3.3	6
47	FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 77-86.	2.5	13
48	Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. <i>Oncotarget</i> , 2019, 10, 942-952.	1.8	11
49	Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI. <i>Oncology</i> , 2018, 94, 306-310.	1.9	5
50	Molecular pathology of lung cancer: current status and perspectives. <i>Current Opinion in Oncology</i> , 2018, 30, 69-76.	2.4	82
51	Review of cancer treatment with immune checkpoint inhibitors. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 85-91.	1.9	102
52	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	3.2	49
53	Activity of Pembrolizumab in Recurrent Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1196-1202.	2.5	12
54	Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome. <i>Oncotarget</i> , 2018, 9, 21861-21875.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 508-515.	2.2	2
56	Milestones in pathology – from histology to molecular biology. Memo - Magazine of European Medical Oncology, 2017, 10, 42-45.	0.5	7
57	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Molecular Cancer, 2017, 16, 1.	19.2	196
58	Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. American Journal of Hematology, 2017, 92, 885-891.	4.1	47
59	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. Blood, 2017, 129, 371-382.	1.4	24
60	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology, 2017, 4, e595-e606.	4.6	130
61	Next generation sequencing: clinical applications in solid tumours. Memo - Magazine of European Medical Oncology, 2017, 10, 244-247.	0.5	24
62	Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets. Pathology and Oncology Research, 2017, 23, 551-564.	1.9	72
63	Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm. Wiener Klinische Wochenschrift, 2017, 129, 404-410.	1.9	4
64	Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. British Journal of Haematology, 2017, 179, 166-169.	2.5	18
65	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget, 2017, 8, 23061-23072.	1.8	13
66	Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis. Oncotarget, 2017, 8, 47090-47102.	1.8	25
67	Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 191-200.	0.5	6
68	Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?. Clinical Nuclear Medicine, 2016, 41, 837-843.	1.3	18
69	Programmed death-ligand 1 expression in rectal cancer. European Surgery - Acta Chirurgica Austriaca, 2016, 48, 352-356.	0.7	15
70	FISH Technique as Additional Diagnostic Tool in Differentiating Testicular Pulmonary Metastasis from Pulmonary Congenital Cystic Adenomatoid Malformation. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, e16-e17.	1.2	1
71	Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?. Clinical Nuclear Medicine, 2016, 41, 101-105.	1.3	20
72	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 2879-2885.	2.4	7

#	ARTICLE	IF	CITATIONS
73	Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 69976-69990.	1.8	27
74	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. <i>Medicine (United States)</i> , 2015, 94, e2388.	1.0	24
75	Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e130-e132.	1.6	8
76	The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor- $\kappa$ B. <i>Leukemia and Lymphoma</i> , 2015, 56, 1440-1449.	1.3	3
77	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. <i>Annals of Hematology</i> , 2015, 94, 223-231.	1.8	20
78	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT- $\alpha$ Controlled Prospective Study in 64 Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2506-2513.	7.0	78
79	Adenocarcinoma of the Thymus, Enteric Type. <i>American Journal of Surgical Pathology</i> , 2015, 39, 541-548.	3.7	43
80	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. <i>Oncotarget</i> , 2015, 6, 394-408.	1.8	27
81	Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 3071-3084.	1.8	50
82	<i>ROS1</i> mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission. <i>Thoracic Cancer</i> , 2014, 5, 455-459.	1.9	3
83	Masked polycythemia vera diagnosed according to WHO and BCSH classification. <i>American Journal of Hematology</i> , 2014, 89, 199-202.	4.1	64
84	Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. <i>American Journal of Hematology</i> , 2014, 89, 344-346.	4.1	20
85	Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. <i>European Journal of Haematology</i> , 2014, 93, 103-111.	2.2	13
86	Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2984-2993.	7.0	100
87	Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Annals of Hematology</i> , 2014, 93, 249-253.	1.8	39
88	Masked polycythemia Vera (MPV): Results of an international study. <i>American Journal of Hematology</i> , 2014, 89, 52-54.	4.1	130
89	Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. <i>Annals of Hematology</i> , 2014, 93, 1287-1295.	1.8	37
90	CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551.	0.5	24

#	ARTICLE	IF	CITATIONS
91	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13.	0.4	12
92	In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology. <i>Blood</i> , 2014, 124, 1822-1822.	1.4	1
93	Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology. <i>PLoS ONE</i> , 2014, 9, e94118.	2.5	30
94	Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients. <i>PLoS ONE</i> , 2014, 9, e104004.	2.5	35
95	Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1771-1775.	2.5	2
96	Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 83-91.	0.5	3
97	Increased copy number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. <i>International Journal of Cancer</i> , 2013, 133, 1380-1388.	5.1	65
98	Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. <i>European Journal of Clinical Investigation</i> , 2013, 43, 277-285.	3.4	59
99	B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C $\delta$ . <i>Blood</i> , 2013, 121, 3112-3116.	1.4	118
100	t(11;14)(q23;q32) involving <i>IGH</i> and <i>DDX6</i> in nodal marginal zone lymphoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 33-43.	2.8	13
101	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013, 34, 513-521.	2.8	67
102	A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). <i>Haematologica</i> , 2013, 98, 353-356.	3.5	81
103	ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. <i>Haematologica</i> , 2013, 98, 50-56.	3.5	112
104	Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie. <i>Haematologica</i> , 2013, 98, 264-268.	3.5	36
105	Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms. <i>Blood</i> , 2013, 122, 3747-3747.	1.4	1
106	$\beta$ 2-T-cell Lymphoma Mimicking SÅzary Syndrome. <i>Acta Dermato-Venereologica</i> , 2012, 92, 166-168.	1.3	2
107	Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. <i>FASEB Journal</i> , 2012, 26, 894-906.	0.5	40
108	Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma. <i>Haematologica</i> , 2012, 97, 766-770.	3.5	12

#	ARTICLE	IF	CITATIONS
109	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012, 119, 2239-2241.	1.4	90
110	A prognostic model to predict survival in 867 World Health Organizationâ€‘defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012, 120, 1197-1201.	1.4	222
111	<i>Helicobacter pylori</i> eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860.	1.4	58
112	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. <i>Blood</i> , 2012, 120, e28-e34.	1.4	199
113	Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects. <i>Annals of Hematology</i> , 2012, 91, 1817-1818.	1.8	8
114	Leukocytosis as an important risk factor for arterial thrombosis in WHOâ€‘defined early/prefibrotic myelofibrosis: An international study of 264 patients. <i>American Journal of Hematology</i> , 2012, 87, 669-672.	4.1	49
115	Plasmacytic differentiation in MALT lymphomas following treatment with rituximab. <i>Annals of Hematology</i> , 2012, 91, 723-728.	1.8	18
116	Extranodal marginal zone lymphoma of the CNS arising after a long-standing history of atypical white matter disease. <i>Leukemia Research</i> , 2012, 36, e155-e157.	0.8	10
117	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). <i>Oncotarget</i> , 2012, 3, 1588-1599.	1.8	144
118	Running in the family: MALT lymphoma and autoimmune disease in mother and daughter. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 26.	2.0	2
119	Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2011, 178, 2344-2356.	3.8	36
120	Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial. <i>American Journal of Surgical Pathology</i> , 2011, 35, 836-844.	3.7	54
121	Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. <i>Blood</i> , 2011, 117, 5710-5718.	1.4	163
122	Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosis. <i>Annals of Hematology</i> , 2011, 90, 947-954.	1.8	4
123	Clinicopathological aspects of mucosaâ€‘associated lymphoid tissue (MALT) lymphoma of the parotid gland: A retrospective singleâ€‘center analysis of 28 cases. <i>Head and Neck</i> , 2011, 33, 763-767.	2.0	25
124	Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. <i>Modern Pathology</i> , 2011, 24, 585-595.	5.5	131
125	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3179-3184.	1.6	441
126	Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. <i>Haematologica</i> , 2011, 96, 672-680.	3.5	17



#	ARTICLE	IF	CITATIONS
127	Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. <i>American Journal of Cancer Research</i> , 2011, 1, 531-41.	1.4	11
128	Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. <i>Annals of Hematology</i> , 2010, 89, 163-169.	1.8	16
129	Host Defense Mechanisms in Secondary Syphilitic Lesions. <i>American Journal of Pathology</i> , 2010, 177, 2421-2432.	3.8	42
130	Rituximab Plus Dose-Reduced Cyclophosphamide, Mitoxantrone, Vincristine, and Prednisolone Are Effective in Elderly Patients with Diffuse Large B-Cell Lymphoma of the Thyroid. <i>Thyroid</i> , 2010, 20, 425-427.	4.5	17
131	A phase II study of bortezomib in patients with MALT lymphoma. <i>Haematologica</i> , 2009, 94, 738-742.	3.5	70
132	Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. <i>Blood</i> , 2009, 114, 3854-3863.	1.4	91
133	Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. <i>Human Pathology</i> , 2008, 39, 917-924.	2.0	17
134	Genome-Wide Transcriptional Response to 5-Aza-2-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells. <i>Cancer Research</i> , 2008, 68, 44-54.	0.9	157
135	Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of <i>ODZ2</i> , <i>JMJD2C</i> , and <i>CNN3</i> . <i>Clinical Cancer Research</i> , 2008, 14, 6426-6431.	7.0	127
136	Autoimmune Lymphoproliferative Syndrome (ALPS) Caused by Fas (CD95) Mutation Mimicking Sarcoidosis. <i>American Journal of Surgical Pathology</i> , 2008, 32, 329-334.	3.7	9
137	Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2007, 142, 158-164.	2.1	111
138	Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. <i>Blood</i> , 2007, 109, 3031-3041.	1.4	64
139	A mimic of sarcoidosis. <i>Lancet, The</i> , 2007, 369, 1832.	13.7	15
140	Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface. <i>Leukemia Research</i> , 2007, 31, 1461-1468.	0.8	90
141	Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. <i>Leukemia and Lymphoma</i> , 2006, 47, 451-460.	1.3	41
142	Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia. <i>American Journal of Pathology</i> , 2006, 168, 123-130.	3.8	40
143	Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. <i>Human Pathology</i> , 2006, 37, 439-447.	2.0	14
144	Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFR $\beta$ , classification by WHO criteria, and response to therapy with imatinib. <i>Leukemia Research</i> , 2006, 30, 1201-1205.	0.8	37

#	ARTICLE	IF	CITATIONS
145	Myeloid sarcoma with multiple lesions of the central nervous system in a patient without leukemia. <i>Journal of Neurosurgery</i> , 2006, 105, 916-919.	1.6	36
146	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	50
147	Identification of Basogranulin (BB1) as a Novel Immunohistochemical Marker of Basophils in Normal Bone Marrow and Patients With Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2006, 125, 273-281.	0.7	16
148	FAS (CD95) Mutations Are Rare in Gastric MALT Lymphoma but Occur More Frequently in Primary Gastric Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 1081-1089.	3.8	36
149	Mutations in apoptosis genes: a pathogenetic factor for human disease. <i>Mutation Research - Reviews in Mutation Research</i> , 2001, 488, 211-231.	5.5	130
150	Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. <i>Journal of Pathology</i> , 2000, 190, 20-30.	4.5	71
151	Author's reply. <i>Journal of Pathology</i> , 2000, 191, 469-470.	4.5	1
152	Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. <i>Human Pathology</i> , 2000, 31, 448-455.	2.0	29
153	Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. , 2000, 190, 20.		2
154	Hyperdiploidy and apparent aneusomy in mesothelial cells from non-malignant effusions as detected by fluorescence in situ hybridization (FISH). , 1999, 38, 15-23.		9
155	Levels of transforming growth factor $\hat{I}^2$ and transforming growth factor $\hat{I}^2$ receptors in rat liver during growth, regression by apoptosis and neoplasia. <i>Hepatology</i> , 1998, 28, 717-726.	7.3	56
156	SELECTIVE REGRESSION OF LIVER TUMORS BY APOPTOSIS DUE TO AN INHERENT ACCELERATION OF CELL TURNOVER. <i>Biochemical Society Transactions</i> , 1996, 24, 606S-606S.	3.4	0
157	Functions of [His321]Gelsolin Isolated from a Flat Revertant of <i>ras</i> -Transformed Cells. <i>FEBS Journal</i> , 1995, 229, 615-620.	0.2	3
158	Functions of [His321]Gelsolin Isolated from a Flat Revertant of <i>ras</i> -Transformed Cells. <i>FEBS Journal</i> , 1995, 229, 615-620.	0.2	18
159	Active cell death: role in hepatocarcinogenesis and subtypes. <i>Biochemistry and Cell Biology</i> , 1994, 72, 669-675.	2.0	25
160	A specific protein, p92, detected in flat revertants derived from NIH/3T3 transformed by human activated c-Ha-ras oncogene. <i>Experimental Cell Research</i> , 1990, 186, 115-121.	2.6	23
161	Elevated gelsolin and $\hat{I}^{\pm}$ -actin expression in a flat revertant R1 of Ha-ras oncogene-transformed NIH3T3 cells. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 852-859.	2.1	11